Sort
46,585 grants matching “heart failure”
The NKA Interactome in Health and Disease
$672,608Seth L Robia · Loyola University Chicago · R01 · FY2025 · HL
Advanced Kidney Health Monitoring in Persons Hospitalized with Heart Failure
$672,601Michelle M Estrella · Northern California Institute/Res/Edu · R01 · FY2025 · DK
Contributions of pulmonary arterial and venous remodeling to HFpEF in the elderly
$672,558Amil M Shah · Ut Southwestern Medical Center · R01 · FY2025 · HL
Hemopexin as an Early Biomarker of Anthracycline Cardiac Toxicity
$672,532Aarti Asnani · Beth Israel Deaconess Medical Center · R01 · FY2022 · HL
PDE5A Inhibition Stimulates Stem Cell Survival & Differentiation
$672,509Muhammad Ashraf · University Of Cincinnati · R01 · FY2009 · HL
IP3 receptor, NOX2 and calcium signaling domains in atrial physiology and pathophysiology
$672,443Lothar A Blatter · Rush University Medical Center · R01 · FY2022 · HL
Cardiac Toxicity in Perinatally HIV-Infected Adolescents and Young Adults, a Longitudinal Study
$672,429Steven Edward Lipshultz · State University Of New York At Buffalo · R01 · FY2020 · HL
Implementing Effective Smoking Cessation Pharmacotherapy for Hospitalized Smokers with Cardiopulmonary Disease
$672,304Quinn Russell Pack · Baystate Medical Center, Inc. · R01 · FY2023 · HL
Impact of Race and Genetic Factors on Beta-blocker Effectiveness in Heart Failure
$672,286David E Lanfear · Henry Ford Health System · R01 · FY2012 · HL
Role of ABCG2 in the disposition and anti-hyperuricemic effects of allopurinol
$672,153Kathleen M Giacomini · University Of California, San Francisco · R01 · FY2016 · DK
Novel Therapeutics for Cardiovascular Disease
$672,130Sasantha Jeson Sangaralingham · Mayo Clinic Rochester · R01 · FY2024 · HL
Pharmacogenetics of the Response to a GLP1R Agonist
$672,029Amber L Beitelshees · University Of Maryland Baltimore · R01 · FY2023 · DK
Pharmacogenetics of the Response to a GLP1R Agonist
$672,029Simeon I Taylor · University Of Maryland Baltimore · R01 · FY2022 · DK
HEART Camp Connect: Promoting Adherence to Exercise in Adults with Heart Failure with Preserved Ejection Fraction
$672,027Windy Williams Alonso · University Of Nebraska Medical Center · R01 · FY2025 · HL
Identifying Effective Strategies to Disclose Prognosis in Patients with ARDS
$671,962Douglas B White · University Of Pittsburgh At Pittsburgh · R01 · FY2012 · HL
Inverse neurovascular coupling in the hypothalamus and its role in positive feedback regulation of Vasopressin neurons in health and disease
$671,936Javier E Stern · Georgia State University · R01 · FY2025 · HL
Inverse neurovascular coupling in the hypothalamus and its role in positive feedback regulation of Vasopressin neurons in health and disease
$671,936Javier E Stern · Georgia State University · R01 · FY2023 · HL
The state of energy in the right ventricle of patients with pulmonary arterial hypertension
$671,932Arash Kheradvar · University Of California-Irvine · R01 · FY2022 · HL
Subclinical Atherosclerosis in HIV plus Black Cocaine Users
$671,860Shenghan Lai · Johns Hopkins University · R01 · FY2012 · DA
Fibroblast targeting for myocardial repair
$671,837Francis G Spinale · University Of South Carolina At Columbia · R01 · FY2023 · HL
Behavioral Economics and Implementation Research to Reduce Cardiovascular Risk in HIV-infected Adults
$671,825Joseph Abiodun Ladapo · University Of California Los Angeles · U01 · FY2020 · HL
Physician Subspecialization and the Health and Health Care of Older Americans
$671,795Michael Lawrence Barnett · Harvard School Of Public Health · R01 · FY2022 · AG
Fibroblasts and Mononuclear Fibrogenic Cells Drive Right Ventricular Pulmonary Ar
$671,793Kurt R Stenmark · University Of Colorado Denver · R01 · FY2014 · HL
Supportive Tailored Exercise Program for Survivors of Breast Cancer (STEPS-BC)
$671,757William Gregory Hundley · Virginia Commonwealth University · R01 · FY2025 · CA
Dissecting the mechanisms underlying fentanyl-induced cardiorespiratory depression
$671,732Jose A Moron-Concepcion · Washington University · R01 · FY2025 · DA